$ACRS

Cantor Fitzgerald reiterated an Overweight rating on Aclaris Therapeutics (ACRS), citing its promising pipeline. The stock is down 14% this week but up 140% over a year. Analysts highlight potential in its atopic dermatitis and asthma treatments, with key data expected in 2026. Other firms also issued positive ratings and price targets.

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 6, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Sales Agreement (the “Amended ATM Agreement”) with Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. (“Cantor”

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.

Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the Leerink Partners 2026 Global Healthcare Conference. Dr. Neal Walker, CEO, and other senior leaders will host a fireside chat on March 10, 2026, at 1:40 PM EDT. A live webcast will be available on the company's website.

Aclaris Therapeutics, Inc. participated in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 to provide a strategic overview of its clinical trials and future plans. The company is advancing several drug candidates, including bosakitug and ATI-052 for atopic dermatitis and asthma, and ATI-2138, an ITK/JAK3 inhibitor, for potential use in alopecia and lichen planus. Aclaris aims for a "best-in-class" strategy, differentiating its offerings in a competitive market by focusing on superior efficacy and safety profiles, particularly with its selective ITK inhibitors.

The Atopic Dermatitis Market is projected to reach $31.68 billion by 2033, growing at a CAGR of 13.7% from 2025. This growth is driven by innovation in biologics and small molecules, expanding treatment access, and strong pipeline activity by dermatology-focused companies like Almirall, Aclaris Therapeutics, and Kiniksa Pharmaceuticals. Key trends include a shift towards targeted biologics, increasing emphasis on oral small molecules, and expansion of pediatric indications.

Aclaris Therapeutics has initiated a Phase 1b proof-of-concept trial for its novel bispecific antibody, ATI-052, in patients with moderate-to-severe atopic dermatitis (AD). This follows positive Phase 1a interim results showing a strong safety profile and extended pharmacokinetics. The company also plans to start a second Phase 1b POC trial in asthma this quarter, with top-line results from both expected in the second half of 2026.